Search Results
Aug 28, 2026, 11:41 ET Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)
LISRAYA may cause fetal harm when administered to a pregnant woman. Available data from LISRAYA use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Lactation. There are no data on the presence
More news about: Orsini
Aug 28, 2026, 11:26 ET NeuroRester Announces 75% Sleep Efficiency Boost in Latest Kantar Study
neurorester.com.This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.SUPPORT: Alice Venner, [email protected]
More news about: NeuroRester Corp
Aug 28, 2026, 11:08 ET NICE im Vereinigten Königreich empfiehlt in neuer Leitlinie routinemäßige NHS-Finanzierung für das VitaSmart™ Hypothermic Oxygenated Perfusion System von Bridge to Life
erzielen."Angesichts des breiten Einsatzes in ganz Europa und des rasanten kommerziellen Wachstums in den USA nach der De-Novo-Zulassung durch die Food and Drug Administration (FDA) treibt Bridge to Life weiterhin die evidenzbasierte Forschung zur Organkonservierung voran, um den Spenderpool zu vergrößern und
More news about: Bridge to Life, Ltd.
Aug 28, 2026, 11:00 ET Top 10 Real Estate News: August's Interesting Real Estate News
potential record-setting $237 million. The 13,000-square-foot home, built in 1981 for a Medellín Cartel drug-smuggling pilot, was depicted in Scarface as the over-the-top home of fictional drug king Frank Lopez. And a small home on the property that was later demolished was frequently used by President
More news about: Top Ten Real Estate Deals
Aug 28, 2026, 10:30 ET Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery
Platform Covering the Drug R&D Value ChainAccessible through a single web-based portal, Clicklinks integrates key stages of drug research and development across six core modules:Core Reagents – High-quality research tools and materials.Drug Discovery – Early-stage
More news about: Sanyou Bio
Aug 28, 2026, 08:30 ET Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp Holdings Inc
Aug 28, 2026, 08:03 ET Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
European regulatory authorities to conduct a pivotal clinical trial for TSY-110. TSY-110 is a biosimilar candidate referencing Roche's antibody-drug conjugate (ADC) Kadcyla® (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer.
More news about: Formosa Pharmaceuticals Inc.,
Aug 28, 2026, 08:00 ET HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
capabilitiesThe partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigating an era of compressed timelines and escalating trial costs.SOMERSET,
More news about: Harvest Integrated Research Organization (HiRO)
Aug 28, 2026, 08:00 ET HiRO and Differentia Biotech Forge Strategic Alliance to Redefine Clinical Trial Design Through AI-Powered Simulation
capabilitiesThe partnership unites global clinical operations excellence with advanced digital twin technology, delivering simulation-first drug development to biotech sponsors navigating an era of compressed timelines and escalating trial costs.SOMERSET,
More news about: Harvest Integrated Research Organization (HiRO)
Aug 28, 2026, 07:31 ET Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
areas, optimize resource allocation, and concentrate efforts on high-potential pipeline programs by leveraging its targeted and AI-driven drug discovery platform, drug-device combination platform, and innovative ADC technologies. During the reporting period, multiple pipeline programs achieved positive
More news about: Asieris
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma in August 2020. Paxalisib was also
More news about: Kazia Therapeutics Limited
Aug 28, 2026, 07:00 ET InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation
most of them reported as grade 1-2 and grade 3 TRAEs reported in 30% of patients. No grade 4 TRAEs, treatment-related deaths or TRAEs leading to study drug discontinuation were reported across all cohorts. The most common TRAEs occurring in all 33 patients receiving ifebemtinib plus garsorasib were diarrhoea,
More news about: InxMed Co., Ltd
Aug 28, 2026, 07:00 ET FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
INDIANAPOLIS, Aug. 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse
More news about: Eli Lilly and Company
Aug 28, 2026, 06:03 ET Tigermed Announces 2026 Interim Results
among the global Top 10.Business OverviewIn the clinical trial solutions field, as of June 30, 2026, the number of ongoing drug clinical research projects was 667. The number of total customers served in Regulatory Affairs increased to 1,014, and the Company added 28 new U.S.
More news about: Hangzhou Tigermed Consulting Co., Ltd.
Aug 28, 2026, 06:00 ET IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop
More news about: IDEAYA Biosciences, Inc.
Aug 28, 2026, 06:00 ET Philips Korea and HoneyNaps Sign Strategic MOU to Advance Sleep and Cardiovascular Health
sleep medicine company that provides solutions for the diagnosis and analysis of sleep disorders based on AI technology authorized by the U.S. Food and Drug Administration. The company has developed an end-to-end sleep healthcare platform encompassing biosignal sensing, analysis, diagnosis, and treatment.
More news about: HoneyNaps
Aug 28, 2026, 05:56 ET Tigermed Announces 2026 Interim Results
among the global Top 10.Business OverviewIn the clinical trial solutions field, as of June 30, 2026, the number of ongoing drug clinical research projects was 667. The number of total customers served in Regulatory Affairs increased to 1,014, and the Company added 28 new U.S.
More news about: Hangzhou Tigermed Consulting Co., Ltd.
Aug 28, 2026, 05:32 ET La Food and Drug Administration statunitense ha accettato la domanda di autorizzazione per un nuovo farmaco denominato "K-911", destinato a pazienti affetti da glaucoma e ipertensione oculare
annunciato oggi che la New Drug Application (NDA) presentata alla U.S. Food and Drug Administration (FDA) il 30 giugno 2026 è stata accettata per la presentazione. La FDA effettuerà la sua revisione dell'NDA con una data di azione target del 30 aprile 2027, ai sensi del Prescription Drug User Fee Act (PDUFA).
More news about: Kowa Company Ltd.
Aug 28, 2026, 04:14 ET La demande d'autorisation de mise sur le marché du « K-911 », destiné aux patients atteints de glaucome et d'hypertension oculaire, a été acceptée par la Food and Drug Administration (FDA) aux États-Unis
Caroline du Nord, aux États-Unis). Kowa a annoncé aujourd'hui que la demande d'autorisation de mise sur le marché (AMM) déposée auprès de la Food and Drug Administration (FDA) américaine le 30 juin 2026 a été acceptée. La FDA procédera à l'examen de l'AMM avec une date cible de décision fixée au 30 avril
More news about: Kowa Company Ltd.
Aug 28, 2026, 03:00 ET Evonik expands lipid-based drug delivery capabilities with new GMP manufacturing facility in Vancouver
ESSEN, Germany, Aug. 28, 2026 /PRNewswire/ -- Evonik is investing in a new GMP drug product manufacturing facility for lipid-based drug delivery in Vancouver, Canada. The facility will increase Evonik's development and manufacturing capacity, helping
More news about: Evonik Industries AG
Aug 28, 2026, 03:00 ET Evonik abre una nueva planta de fabricación con certificación GMP en Vancouver
Evonik expands lipid-based drug delivery capabilities Lea más sobre el ecosistema
More news about: Evonik Industries AG
Aug 28, 2026, 01:03 ET Zulassungsantrag für „K-911" zur Behandlung von Patienten mit Glaukom und okulärer Hypertonie von der U.S. Food and Drug Administration zur Prüfung angenommen
heute bekannt, dass der am 30. Juni 2026 bei der U.S. Food and Drug Administration (FDA) eingereichte Zulassungsantrag (New Drug Application, NDA) zur Prüfung angenommen wurde. Die FDA wird den Zulassungsantrag (NDA) gemäß dem Prescription Drug User Fee Act (PDUFA) prüfen; als Zieldatum für die Entscheidung
More news about: Kowa Company Ltd.
Aug 28, 2026, 00:08 ET DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate ("DUPAC") platform. DUPAC is one of DualityBio's
More news about: Duality Biotherapeutics, Inc.
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued
More news about: Akeso, Inc.
Aug 27, 2026, 21:01 ET /C O R R E C T I O N -- O Positiv Health/
TikTok at @opositiv.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.†Serevelle™ and ActiLipid4Hair™
More news about: O Positiv Health